DAPK2 regulates oxidative stress in cancer cells by preserving mitochondrial function

por Schlegel, C R, Georgiou, M L, Misterek, M B, Stöcker, S, Chater, E R, Munro, C E, Pardo, O E, Seckl, M J, Costa-Pereira, A P
Publicado 2015

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

por Coombes, R. C., Badman, P. D., Lozano-Kuehne, J. P., Liu, X., Macpherson, I. R., Zubairi, I., Baird, R. D., Rosenfeld, N., Garcia-Corbacho, J., Cresti, N., Plummer, R., Armstrong, A., Allerton, R., Landers, D., Nicholas, H., McLellan, L., Lim, A., Mouliere, F., Pardo, O. E., Ferguson, V., Seckl, M. J.
Publicado 2022

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

por Coombes, R. C., Badman, P. D., Lozano-Kuehne, J. P., Liu, X., Macpherson, I. R., Zubairi, I., Baird, R. D., Rosenfeld, N., Garcia-Corbacho, J., Cresti, N., Plummer, R., Armstrong, A., Allerton, R., Landers, D., Nicholas, H., McLellan, L., Lim, A., Mouliere, F., Pardo, O. E., Ferguson, V., Seckl, M. J.
Publicado 2023